JP2021520831A5 - - Google Patents
Info
- Publication number
- JP2021520831A5 JP2021520831A5 JP2020556864A JP2020556864A JP2021520831A5 JP 2021520831 A5 JP2021520831 A5 JP 2021520831A5 JP 2020556864 A JP2020556864 A JP 2020556864A JP 2020556864 A JP2020556864 A JP 2020556864A JP 2021520831 A5 JP2021520831 A5 JP 2021520831A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- tcr
- seq
- treg
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806331.3A GB201806331D0 (en) | 2018-04-18 | 2018-04-18 | Method |
| GB1806331.3 | 2018-04-18 | ||
| GBGB1806330.5A GB201806330D0 (en) | 2018-04-18 | 2018-04-18 | Engineered regulatory T cell |
| GB1806330.5 | 2018-04-18 | ||
| PCT/GB2019/051097 WO2019202322A1 (en) | 2018-04-18 | 2019-04-17 | Engineered regulatory t cell |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520831A JP2021520831A (ja) | 2021-08-26 |
| JP2021520831A5 true JP2021520831A5 (enExample) | 2022-03-31 |
| JP7436383B2 JP7436383B2 (ja) | 2024-02-21 |
Family
ID=66286535
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556864A Active JP7436383B2 (ja) | 2018-04-18 | 2019-04-17 | 操作された調節性ｔ細胞 |
| JP2020556883A Active JP7391038B2 (ja) | 2018-04-18 | 2019-04-17 | Ｔｒｅｇ細胞の抑制特性を増強するための方法 |
| JP2023197319A Active JP7839774B2 (ja) | 2018-04-18 | 2023-11-21 | Ｔｒｅｇ細胞の抑制特性を増強するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556883A Active JP7391038B2 (ja) | 2018-04-18 | 2019-04-17 | Ｔｒｅｇ細胞の抑制特性を増強するための方法 |
| JP2023197319A Active JP7839774B2 (ja) | 2018-04-18 | 2023-11-21 | Ｔｒｅｇ細胞の抑制特性を増強するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US12227756B2 (enExample) |
| EP (2) | EP3781673A1 (enExample) |
| JP (3) | JP7436383B2 (enExample) |
| KR (1) | KR20210003810A (enExample) |
| CN (2) | CN112004924A (enExample) |
| AU (2) | AU2019254824B2 (enExample) |
| CA (2) | CA3105303A1 (enExample) |
| GB (3) | GB2611707A (enExample) |
| IL (1) | IL278016B2 (enExample) |
| SG (1) | SG11202010154UA (enExample) |
| WO (2) | WO2019202322A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7436383B2 (ja) | 2018-04-18 | 2024-02-21 | ユーシーエル ビジネス リミテッド | 操作された調節性ｔ細胞 |
| EP3921427A1 (en) * | 2019-02-05 | 2021-12-15 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Recombinant vectors suitable for the treatment of ipex syndrome |
| GB201915359D0 (en) * | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Engineered regulatory t cell |
| PL241050B1 (pl) * | 2019-12-12 | 2022-07-25 | Gdanski Univ Medyczny | Zastosowanie limfocytów T regulatorowych jako leku w leczeniu stwardnienia rozsianego |
| AU2021373326A1 (en) * | 2020-11-09 | 2023-06-22 | Quell Therapeutics Ltd | Method for cryopreserving engineered tregs |
| US20220169687A1 (en) | 2020-11-10 | 2022-06-02 | Kyverna Therapeutics, Inc. | Method for treating disease using foxp3+cd4+ t cells |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| AU2022349176A1 (en) * | 2021-09-27 | 2024-04-11 | Kyoto University | Method for producing t cell |
| US20250017967A1 (en) | 2021-12-17 | 2025-01-16 | Quell Therapeutics Limited | Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells |
| US20230210900A1 (en) * | 2022-01-04 | 2023-07-06 | Kyverna Therapeutics, Inc. | Methods for treating autoimmune diseases |
| EP4496883A1 (en) | 2022-03-22 | 2025-01-29 | Quell Therapeutics Limited | Methods and products for culturing t cells and uses thereof |
| CN119325506A (zh) * | 2022-05-05 | 2025-01-17 | 圭尔医疗有限公司 | 维持调节性t细胞的抑制活性的方法 |
| CN116284447A (zh) * | 2023-02-20 | 2023-06-23 | 苏州大学 | 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用 |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| EP1105479B1 (en) | 1998-08-11 | 2011-01-12 | Darwin Discovery Limited | Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| EP1967525B1 (en) | 2001-05-08 | 2012-11-14 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
| FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
| JP2007515946A (ja) | 2003-06-13 | 2007-06-21 | オンコマックス アクイジション コーポレイション | 抗腫瘍二元機能融合タンパク質の調製および適用 |
| NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| US8053197B2 (en) * | 2004-07-30 | 2011-11-08 | Oregon Health & Science University | Methods for detecting and treating autoimmune disorders |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| BRPI0610203A2 (pt) | 2005-05-24 | 2010-06-01 | Avestha Gengraine Tech Pvt Ltd | processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica |
| EP2126054B1 (en) * | 2007-01-31 | 2016-07-06 | Yeda Research And Development Company Limited | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| JP5626164B2 (ja) | 2011-07-26 | 2014-11-19 | 日本精工株式会社 | ステアリングコラム用支持装置 |
| US20150073043A1 (en) | 2012-01-19 | 2015-03-12 | Institut Pasteur Of Shanghai, Chinese Academy Of Sciences | Use of phosphorylation pathway-related factor in regulating function of regulatory t cell |
| RU2523058C2 (ru) | 2012-06-29 | 2014-07-20 | Общество с ограниченной ответственностью "Регенекс" | Способ терапии ремиттирующего рассеянного склероза |
| WO2014145970A1 (en) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Modulation of regulatory t cells via g-coupled protein receptor 43 |
| US10093901B2 (en) * | 2013-05-10 | 2018-10-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Use of specific regulatory T-cells to induce immune tolerance |
| GB201322430D0 (en) * | 2013-12-18 | 2014-02-05 | Immunocore Ltd | T cell receptors |
| HK1245827B (en) | 2014-12-15 | 2020-06-19 | Board Of Regents Of The University Of Texas System | Methods for controlled activation or elimination of therapeutic cells |
| WO2016133779A1 (en) | 2015-02-16 | 2016-08-25 | The Trustees Of The University Of Pennsylvania | A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| US11365391B2 (en) | 2015-09-28 | 2022-06-21 | Trustees Of Dartmouth College | Chimeric antigen receptor anti-inflammatory cells and methods of use |
| WO2017062035A1 (en) | 2015-10-09 | 2017-04-13 | Abt Holding Company | Methods for enhancing proliferation of t regulatory cells |
| US10604586B2 (en) | 2016-05-09 | 2020-03-31 | Industrial Technology Research Institute | Humanized monoclonal antibody and uses thereof |
| EP3263595A1 (en) | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
| AU2017291262A1 (en) | 2016-06-30 | 2019-01-03 | F. Hoffmann-La Roche Ag | Improved adoptive T-cell therapy |
| EP3714944A1 (en) | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| WO2018231759A1 (en) | 2017-06-12 | 2018-12-20 | Obsidian Therapeutics, Inc. | Pde5 compositions and methods for immunotherapy |
| WO2018236909A1 (en) | 2017-06-20 | 2018-12-27 | La Jolla Institute For Allergy And Immunology | Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis |
| WO2019079034A1 (en) | 2017-10-17 | 2019-04-25 | The General Hospital Corporation | METHODS AND COMPOSITIONS RELATING TO GENETICALLY MODIFIED REGULATORY T LYMPHOCYTES |
| JP7436383B2 (ja) | 2018-04-18 | 2024-02-21 | ユーシーエル ビジネス リミテッド | 操作された調節性ｔ細胞 |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| JP2022533713A (ja) | 2019-05-21 | 2022-07-25 | サンガモ セラピューティクス， インコーポレイテッド | 調節性ｔ細胞における制御された導入遺伝子発現 |
| GB201915359D0 (en) * | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Engineered regulatory t cell |
| GB201915384D0 (en) | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Vector |
| GB202007842D0 (en) | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
-
2019
- 2019-04-17 JP JP2020556864A patent/JP7436383B2/ja active Active
- 2019-04-17 IL IL278016A patent/IL278016B2/en unknown
- 2019-04-17 SG SG11202010154UA patent/SG11202010154UA/en unknown
- 2019-04-17 US US17/048,587 patent/US12227756B2/en active Active
- 2019-04-17 AU AU2019254824A patent/AU2019254824B2/en active Active
- 2019-04-17 CN CN201980026673.5A patent/CN112004924A/zh active Pending
- 2019-04-17 GB GB2300916.0A patent/GB2611707A/en not_active Withdrawn
- 2019-04-17 WO PCT/GB2019/051097 patent/WO2019202322A1/en not_active Ceased
- 2019-04-17 US US17/048,239 patent/US12077774B2/en active Active
- 2019-04-17 WO PCT/GB2019/051098 patent/WO2019202323A1/en not_active Ceased
- 2019-04-17 JP JP2020556883A patent/JP7391038B2/ja active Active
- 2019-04-17 EP EP19719600.9A patent/EP3781673A1/en active Pending
- 2019-04-17 AU AU2019256783A patent/AU2019256783A1/en not_active Abandoned
- 2019-04-17 CN CN201980041068.5A patent/CN112334571B/zh active Active
- 2019-04-17 CA CA3105303A patent/CA3105303A1/en active Pending
- 2019-04-17 GB GB2300872.5A patent/GB2611498B/en active Active
- 2019-04-17 GB GB2018103.8A patent/GB2587988B/en active Active
- 2019-04-17 EP EP19719599.3A patent/EP3781672B1/en active Active
- 2019-04-17 KR KR1020207032996A patent/KR20210003810A/ko active Pending
- 2019-04-17 CA CA3098128A patent/CA3098128A1/en active Pending
-
2023
- 2023-11-21 JP JP2023197319A patent/JP7839774B2/ja active Active
-
2024
- 2024-08-02 US US18/792,799 patent/US20240384301A1/en active Pending
-
2025
- 2025-01-16 US US19/025,738 patent/US20250154532A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520831A5 (enExample) | ||
| US12297252B2 (en) | T cell receptors with improved pairing | |
| JP2021520198A5 (enExample) | ||
| JP2022502371A5 (enExample) | ||
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| JP2022050400A5 (enExample) | ||
| JP2024522357A5 (enExample) | ||
| JP2020500523A5 (enExample) | ||
| JP2021526816A5 (enExample) | ||
| JP2022527635A5 (enExample) | ||
| FI4219542T3 (fi) | T-solureseptoreja | |
| JP2019511222A5 (enExample) | ||
| JP2023524788A5 (enExample) | ||
| JP2019536437A5 (enExample) | ||
| JP2023522799A5 (enExample) | ||
| JP2018510881A5 (enExample) | ||
| JP2022553540A5 (enExample) | ||
| JP2013505734A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| JP2017505621A5 (enExample) | ||
| JP2024520427A5 (enExample) | ||
| JP2025063321A5 (enExample) | ||
| JP2021531834A5 (enExample) | ||
| JP2022553379A5 (enExample) | ||
| JP2024530325A5 (enExample) |